At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMLX Amylyx Pharmaceuticals
Market Closed 07-10 16:00:00 EDT
17.77
-0.61
-3.32%
盘后18.01
+0.24+1.35%
19:53 EDT
High18.34Low17.15Vol1.07M
Open18.34D1 Closing18.38Amplitude6.45%
Mkt Cap1.98BTradable Cap1.67BTotal Shares111.19M
T/O18.89MT/O Rate1.14%Tradable Shares94.10M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Kodiak Gas Services, Baker Hughes Announce Multi-Year Gas Turbine Order Agreement to Support U.S. Data Center Growth
GlobeNewswire  ·  07-08
Kodiak Gas Services, Baker Hughes Announce Multi-Year Gas Turbine Order Agreement to Support U.S. Data Center Growth
Analysts Are Bullish on These Healthcare Stocks: Amylyx Pharmaceuticals Inc (AMLX), Guardian Pharmacy Services, Inc. Class A (GRDN)
TIPRANKS  ·  07-02
Analysts Are Bullish on These Healthcare Stocks: Amylyx Pharmaceuticals Inc (AMLX), Guardian Pharmacy Services, Inc. Class A (GRDN)
Could Amylyx (AMLX) ALS Safety Data Quietly Reframe Its Neurodegeneration Versus Endocrine Strategy?
Simply Wall St.  ·  06-27
Could Amylyx (AMLX) ALS Safety Data Quietly Reframe Its Neurodegeneration Versus Endocrine Strategy?
Amylyx Pharmaceuticals is Maintained at Buy by Guggenheim
Dow Jones  ·  06-25
Amylyx Pharmaceuticals is Maintained at Buy by Guggenheim
Amylyx reports clean safety in lowest-dose cohort of Phase 1 LUMINA trial of ALS drug AMX0114
Reuters  ·  06-23
Amylyx reports clean safety in lowest-dose cohort of Phase 1 LUMINA trial of ALS drug AMX0114
Amylyx Pharmaceuticals to Present Data From First-in-Human, Dose-Ranging Phase 1 Lumina Trial of Amx0114 in ALS at Encals 2026
THOMSON REUTERS  ·  06-23
Amylyx Pharmaceuticals to Present Data From First-in-Human, Dose-Ranging Phase 1 Lumina Trial of Amx0114 in ALS at Encals 2026
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) and AbCellera Biologics (ABCL)
TIPRANKS  ·  06-18
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) and AbCellera Biologics (ABCL)
Analysts’ Top Healthcare Picks: Amylyx Pharmaceuticals Inc (AMLX), Ascendis Pharma (ASND)
TIPRANKS  ·  06-16
Analysts’ Top Healthcare Picks: Amylyx Pharmaceuticals Inc (AMLX), Ascendis Pharma (ASND)
Amylyx to present avexitide Phase 3 LUCIDITY trial design poster at ENDO 2026
Reuters  ·  06-08
Amylyx to present avexitide Phase 3 LUCIDITY trial design poster at ENDO 2026
Amylyx Pharmaceuticals shareholders elect Milne, Fonteyne as Class II directors
Reuters  ·  06-05
Amylyx Pharmaceuticals shareholders elect Milne, Fonteyne as Class II directors
HELIOS Wolfram Data And Patient Insights Could Be A Game Changer For Amylyx Pharmaceuticals (AMLX)
Simply Wall St.  ·  05-29
HELIOS Wolfram Data And Patient Insights Could Be A Game Changer For Amylyx Pharmaceuticals (AMLX)
Amylyx director Karen Firestone acquires $51,338 of common shares
Reuters  ·  05-27
Amylyx director Karen Firestone acquires $51,338 of common shares
Do HELIOS Data Shift Amylyx (AMLX) From ALS Setback To Broader Rare-Disease Strategy Reboot?
Simply Wall St.  ·  05-22
Do HELIOS Data Shift Amylyx (AMLX) From ALS Setback To Broader Rare-Disease Strategy Reboot?
Amylyx announces publication of Phase 2 open-label HELIOS trial data
TIPRANKS  ·  05-16
Amylyx announces publication of Phase 2 open-label HELIOS trial data
Amylyx posts Phase 2 HELIOS data showing AMX0035 benefits in Wolfram syndrome
Reuters  ·  05-16
Amylyx posts Phase 2 HELIOS data showing AMX0035 benefits in Wolfram syndrome
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label Helios Trial Data for Amx0035 in the Journal of Clinical Investigation
THOMSON REUTERS  ·  05-16
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label Helios Trial Data for Amx0035 in the Journal of Clinical Investigation
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  05-11
Wall Street Analysts Are Bullish on Top Healthcare Picks
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), BioAge Labs, Inc. (BIOA) and Pharvaris (PHVS)
TIPRANKS  ·  05-10
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), BioAge Labs, Inc. (BIOA) and Pharvaris (PHVS)
Stock Track | Amylyx Pharmaceuticals Plummets 8.16% Intraday on Wider-Than-Expected Q1 Loss
Stock Track  ·  05-08
Stock Track | Amylyx Pharmaceuticals Plummets 8.16% Intraday on Wider-Than-Expected Q1 Loss
Amylyx Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-08
Amylyx Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Introduction

Company Name.
Amylyx Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Issue price:
--